Your browser doesn't support javascript.
mRNA Vaccine - A New Cancer Treatment Strategy.
Tan, Tian; Deng, Shu-Ting; Wu, Bing-Huo; Yang, Qi; Wu, Meng-Wan; Wu, Hong; Cao, Chen-Hui; Xu, Chuan.
  • Tan T; School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, China.
  • Deng ST; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610047, China.
  • Wu BH; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610047, China.
  • Yang Q; Biotherapy Center, Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150081, China.
  • Wu MW; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610047, China.
  • Wu H; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610047, China.
  • Cao CH; Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610047, China.
  • Xu C; Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China.
Curr Cancer Drug Targets ; 23(9): 669-681, 2023.
Artículo en Inglés | MEDLINE | ID: covidwho-2287240
ABSTRACT
The corresponding mRNA vaccines Comirnaty (BNT162b2) and Spikevax (mRNA-1273) have been authorized for emergency use since the COVID-19 outbreak. Most clinical researches have also discovered that the mRNA vaccine is a revolutionary strategy for preventing and treating numerous diseases, including cancers. Unlike viral vectors or DNA vaccines, mRNA vaccines cause the body to directly produce proteins following injection. Delivery vectors and mRNAs that encode tumor antigens or immunomodulatory molecules work together to trigger an anti-tumor response. Before mRNA vaccines may be employed in clinical trials, a number of challenges need to be resolved. These include establishing effective and safe delivery systems, generating successful mRNA vaccines against diverse types of cancers, and proposing improved combination therapy. Therefore, we need to improve vaccine-specific recognition and develop mRNA delivery mechanisms. This review summarizes the complete mRNA vaccines' elemental composition and discusses recent research progress and future direction for mRNA tumor vaccines.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Tipo de estudio: Estudio pronóstico Tópicos: Vacunas Límite: Humanos Idioma: Inglés Revista: Curr Cancer Drug Targets Asunto de la revista: Agentes Antineoplásicos / Neoplasmas Año: 2023 Tipo del documento: Artículo País de afiliación: 1568009623666230222124424

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Tipo de estudio: Estudio pronóstico Tópicos: Vacunas Límite: Humanos Idioma: Inglés Revista: Curr Cancer Drug Targets Asunto de la revista: Agentes Antineoplásicos / Neoplasmas Año: 2023 Tipo del documento: Artículo País de afiliación: 1568009623666230222124424